Publications

  1. McWilliams RR, Foster NR, Mahoney MR, Smyrk TC, Murray JA, Ames MM, Horvath LE, Schneider DJ, Hobday TJ, Jatoi A, Meyers JP, Goetz MP. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 2017 Sep 15; 123 (18):3494-3501 Epub 2017 May 10
    View PubMed
  2. Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23 (15):4055-4065 Epub 2017 Mar 07
    View PubMed
  3. Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ, From the CCTG, Alliance, SWOG, ECOG, NSABP Cooperative Groups. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Res Treat. 2017 Jul; 164: (2)371-378.
    View PubMed
  4. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12; 376 (2):125-135
    View PubMed
  5. Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EG, Tomassetti P, Hobday T, Pommier R, Oberg K. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol. 2016 Sep 12; : ().
    View PubMed
  6. Crozier JA, Advani PP, LaPlant B, Hobday T, Jaslowski AJ, Moreno-Aspitia A, Perez EA. N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline andor Taxane-Containing Therapy. Clin Breast Cancer. 2016 Feb; 16: (1)23-30.
    View PubMed
  7. Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33: (24)2623-31.
    View PubMed
  8. Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2015 May 10; 33: (14)1551-6.
    View PubMed
  9. Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015 Mar; 44: (2)181-9.
    View PubMed
  10. Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst. 2015 Mar; 107: (3).
    View PubMed
  11. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015 Jan 01; 33: (1)58-64.
    View PubMed
  12. Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG, Petersen GM. Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study. Pancreas. 2014 Nov; 43: (8)1219-22.
    View PubMed
  13. Yao JC, Pavel M, Lombard-Bohas C, van Cutsem E, Lam D, Kunz T, Brandt U, Capdevila J, De Vries EG, Hobday T, Tomassetti P, Pommier R. 1132OEVEROLIMUS (EVE) FOR THE TREATMENT OF ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET): FINAL OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO (PBO)-CONTROLLED, MULTICENTER PHASE III TRIAL (RADIANT-3). Ann Oncol. 2014 Sep 01; 25: (suppl_4)iv394.
    View PubMed
  14. Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J. 2014 Jun; 14: (3)241-7.
    View PubMed
  15. Leal AD, Kadakia KC, Looker S, Hilger C, Sorgatz K, Anderson K, Jacobson A, Grendahl D, Seisler D, Hobday T, Loprinzi CL. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014 May; 22: (5)1313-7.
    View PubMed
  16. Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA, North Central Cancer Treatment Group. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Am J Clin Oncol. 2014 Apr; 37: (2)167-71.
    View PubMed
  17. Kaur JS, Vierkant RA, Hobday T, Visscher D. Regional differences in breast cancer biomarkers in american Indian and Alaska native women. Cancer Epidemiol Biomarkers Prev. 2014 Mar; 23: (3)409-15.
    View PubMed
  18. Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew D, Gralow J, Hortobagyi GN. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol. 2013 Jun 20; 31: (18_suppl)CRA1008.
    View PubMed
  19. Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Budd GT, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat. 2013 Feb; 137(3):903-13. Epub 2013 Jan 10.
    View PubMed
  20. Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T, RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013; 18(1):46-53. Epub 2012 Dec 21.
    View PubMed
  21. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer. 2012 Dec; 12: (6)387-91.
    View PubMed
  22. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23. Epub 2012 Jun 04.
    View PubMed
  23. Hobday TJ, Qin R, Reidy DL, Moore MJ, Strosberg JR, Kaubisch A, Shah MH, Kindler HL, Lenz HJ, Chen HX, Erlichman C. Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). J Clin Oncol. 2012 Feb; 30: (4_suppl)260.
    View PubMed
  24. Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol. 2012; 2012:973946. Epub 2012 Nov 25.
    View PubMed
  25. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat. 2011 Dec; 130(3):993-1002. Epub 2011 Jul 16.
    View PubMed
  26. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17(22):7183-93. Epub 2011 Oct 05.
    View PubMed
  27. Shah MH, Lombard-Bohas C, Ito T, Wolin EM, Van Cutsem E, Sachs C, Winkler RE, Lincy J, Hobday TJ, Yao JC. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. J Clin Oncol. 2011 May 20; 29: (15_suppl)4010.
    View PubMed
  28. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew D, Gralow J, Hortobagyi GN, SWOG. First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer. J Clin Oncol. 2011 May 20; 29: (15_suppl)1004.
    View PubMed
  29. Lin NU, Mayer IA, Najita JS, Hobday TJ, Falkson CI, Dees EC, Rimawi MF, Nanda R, Gelman RS, Josephs K, Richardson A, Flores L, Van Den Abbeele AD, Yap JT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Translational Breast Cancer Research Consortium. TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). J Clin Oncol. 2011 May 20; 29: (15_suppl)527.
    View PubMed
  30. Krop IE, Flores L, Najita JS, Mayer IA, Hobday TJ, Falkson CI, Arteaga CL, Wolff AC, Dees EC, Rimawi MF, Nanda R, Josephs K, Lin NU, Winer EP, Translational Breast Cancer Research Consortium. The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003. J Clin Oncol. 2011 May 20; 29: (15_suppl)528.
    View PubMed
  31. Hobday TJ, Capdevila J, Saletan S, Panneerselvam A, Pommier RF. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Multivariate analysis of progression-free survival from the RADIANT-3 trial. J Clin Oncol. 2011 May 20; 29: (15_suppl)e21091.
    View PubMed
  32. Parulekar W, Chen BE, Elliott C, Shepherd LE, Gelmon KA, Pritchard KI, Whelan TJ, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Rastogi P, Lemieux J, Ganz PA, Stambolic V, Goodwin PJ. A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32). J Clin Oncol. 2011 May 20; 29: (15_suppl)TPS103.
    View PubMed
  33. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 1; 29(7):934-43. Epub 2011 Jan 24.
    View PubMed
  34. Raymond E, Hobday T, Castellano D, Reidy-Lagunes D, Garcia-Carbonero R, Carrato A. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2011 Mar; 30 Suppl 1:19-26.
    View PubMed
  35. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem, Hobday TJ, Okusaka T, Capdevila J, de Vries, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, RAD001 in. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6):514-23.
    View PubMed
  36. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat. 2011 Feb; 126(1):215-20. Epub 2010 Oct 26.
    View PubMed
  37. Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Sachs C, Winkler RE, Lincy J, Hobday TJ, Yao JC. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3). J Clin Oncol. 2011 Feb; 29: (4_suppl)158.
    View PubMed
  38. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist. 2011; 16(10):1359-66. Epub 2011 Sep 20.
    View PubMed
  39. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter, Haas T, Lebwohl D, Van Cutsem, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 1; 28(1):69-76. Epub 2009 Nov 23.
    View PubMed
  40. Reinholz MM, Kitzmann KA, Hobday TJ, Northfelt DW, LaPlant B, Allred JB, Dueck AC, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 (CK19) and mammaglobin (MGB1) gene expression in circulating tumor cells (CTCs) from metastatic breast cancer patients enrolled in the NCCTG trials, N0436 and N0437. J Clin Oncol. 2009 May 20; 27: (15_suppl)11095.
    View PubMed
  41. Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. Clin Colorectal Cancer. 2009 Mar; 8(2):88-93.
    View PubMed
  42. Walia T, Quevedo JF, Hobday TJ, Croghan G, Jatoi A. Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy. Ther Clin Risk Manag. 2008 Dec; 4(6):1363-6.
    View PubMed
  43. Northfelt DW, Allred JB, Liu H, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA. Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC). J Clin Oncol. 2008 May 20; 26: (15_suppl)1063.
    View PubMed
  44. Hobday TJ, Stella PJ, Fitch TR, Jaslowski A, LaPlant B, Ames MM, Goetz MP, Perez EA. N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. J Clin Oncol. 2008 May 20; 26: (15_suppl)1081.
    View PubMed
  45. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008 Feb; 103(2):475-83; quiz 484. Epub 2007 Nov 19.
    View PubMed
  46. Stilling GA, Zhang H, Ruebel KH, Leontovich AA, Jin L, Tanizaki Y, Zhang S, Erickson LA, Hobday T, Lloyd RV. Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors. Endocr Pathol. 2007 Winter; 18(4):223-32.
    View PubMed
  47. Bernheim AM, Connolly HM, Hobday TJ, Abel MD, Pellikka PA. Carcinoid heart disease. Prog Cardiovasc Dis. 2007 May-Jun; 49(6):439-51.
    View PubMed
  48. Zhang HY, Rumilla KM, Jin L, Nakamura N, Stilling GA, Ruebel KH, Hobday TJ, Erlichman C, Erickson LA, Lloyd RV. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors. Endocrine. 2006 Dec; 30(3):299-306.
    View PubMed
  49. Hobday TJ, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman C. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)4043.
    View PubMed
  50. Moreno-Aspitia A, Hillman DW, Wiesenfeld M, Hobday TJ, Rowland KM, Northfelt DW, Tenner KS, Palmieri FM, Perez EA. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)577.
    View PubMed
  51. Smoot RL, Koch CA, Degnim AC, Sterioff S, Donohue JH, Grant CS, Barnes SA, Gullerud RE, Hobday TJ, Farley DR. A single-center experience with inflammatory breast cancer, 1985-2003. Arch Surg. 2006 Jun; 141(6):567-72; discussion 572-3.
    View PubMed
  52. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ, Hobday TJ. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl. 2006 Mar; 12(3):448-56.
    View PubMed
  53. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005 Oct; 18(10):1329-35.
    View PubMed
  54. Atwell TD, Charboneau JW, Que FG, Rubin J, Lewis BD, Nagorney DM, Callstrom MR, Farrell MA, Pitot HC, Hobday TJ. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol. 2005 Jul-Aug; 28(4):409-21.
    View PubMed
  55. Hobday TJ, Mahoney M, Erlichman C, Lloyd R, Kim G, Mulkerin D, Picus J, Fitch T, Donehower R. Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol. 2005 Jun; 23: (16_suppl)4083.
    View PubMed
  56. Graham DL, Hillman DW, Hobday TJ, Rousey SR, Nair SG, Soori GS, Sabagh TM, Perez EA. N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). J Clin Oncol. 2005 Jun; 23: (16_suppl)644.
    View PubMed
  57. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005 Apr; 80(4):502-6.
    View PubMed
  58. Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer. 2005 Apr; 5 Suppl 1:S11-8.
    View PubMed
  59. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control. 2005 Apr; 12(2):73-81.
    View PubMed
  60. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003 Dec; 78(12):1578-9.
    View PubMed
  61. Hobday TJ. The role of oxaliplatin/5-fluorouracil/leucovorin in the therapy of colorectal cancer. Adv Colorect Cancer. 2003; 7(1):3-6.
  62. Hobday TJ, Kugler JW, Mahoney MR, Sargent DJ, Sloan JA, Fitch TR, Krook JE, O'Connell MJ, Mailliard JA, Tirona MT, Tschetter LK, Cobau CD, Goldberg RM. Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol. 2002 Dec 1; 20: (23)4574-80.
    View PubMed
  63. Hobday TJ, Goldberg RM. Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. Clin Colorectal Cancer. 2002 Nov; 2: (3)161-9.
    View PubMed
  64. Hobday TJ, Erlichman C. Adjuvant therapy of colon cancer: a review. Clin Colorectal Cancer. 2002 Feb; 1: (4)230-6.
    View PubMed
  65. Hobday TJ, Pellikka PA, Attenhofer Jost CH, Oh JK, Miller FA Jr, Seward JB. Chronotropic response, safety, and accuracy of dobutamine stress echocardiography in patients with atrial fibrillation and known or suspected coronary artery disease. Am J Cardiol. 1998 Dec 01; 82: (11)1425-7, A9.
    View PubMed
  66. Hobday TJ, Heser JL, Rooke TW. The use of laser Doppler flowmetry and transcutaneous oxygen measurements to evaluate the efficacy of sympathectomy in the treatment of arterial occlusive disease. J Vasc Technol. 1994; 18:19-22.